Quick Answer
Enliven Therapeutics, Inc. reported Shares Outstanding of 59.44 million shares for fiscal year 2025.
Enliven Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 59.44M | +21.5% |
| 2024 | 48.94M | +18.5% |
| 2023 | 41.29M | +0.7% |
| 2023 | 41.01M | +1048.8% |
| 2022 | 3.57M | -86.4% |
| 2021 | 26.29M | +49.8% |
| 2020 | 17.55M | +2397.9% |
| 2019 | 702,510 | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 59.26M | +25.4% | +0.1% |
| June 30, 2025 | 59.23M | +25.5% | +20.8% |
| March 31, 2025 | 49.04M | +4.8% | +0.2% |
| December 31, 2024 | 48.94M | +18.5% | +3.6% |
| September 30, 2024 | 47.25M | +14.7% | +0.2% |
| June 30, 2024 | 47.17M | +14.6% | +0.8% |
| March 31, 2024 | 46.78M | +13.8% | +13.3% |
| December 31, 2023 | 41.29M | — | +0.2% |
- Enliven Therapeutics, Inc. showed an increase of +21.5% in Shares Outstanding compared to the prior fiscal year.
- Over the 2019–2025 period, Enliven Therapeutics, Inc.’s shares outstanding has grown by 8361.1% (from 702.5 thousand shares to 59.44 million shares).
- The most recent figure is from Enliven Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: